No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Wow…

Sep 23, 2024 10:38AM
1
Sep 23, 2024 11:59AM

Sep 23, 2024 10:19PM
1
Sep 24, 2024 07:07AM
1
Sep 24, 2024 10:07AM

What's new? Waiting for the first sign of new money for BOM2 outside of Zenith. Going the Zenith route for its funding is premature unless a BP cuts things off at the pass and buys into ZEN-3694 before ZEN-3694 can prove itself clinically. I'm just holding on to both RVX and ZHCLF and adding some from time to time. As the proverb goes, patience is a virtue. :)

 

Koo


Sep 25, 2024 12:10PM
4
Sep 25, 2024 01:18PM
Share
New Message
Please login to post a reply